Prothena Corporation plc
NASDAQ:PRTA · NASDAQ Global Select
+$0.33 today
Vol 1.13M · Avg 0.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PRTA · Revenue to Net Income
Key Ratios
Analysis
$57.9M of revenue converted into -$151.2M of net income for the selected period. Gross margin is -1321.4% and net margin is -26774.8%, showing how much revenue survives after costs and taxes. EPS is $-2.82, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M -92.8% | $135.2M +47.9% | $91.4M +69.5% | $53.9M -73.1% | $200.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.7M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $6.0M -95.6% | $135.2M +47.9% | $91.4M +69.5% | $53.9M -73.1% | $200.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.8% -38.2pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $134.9M -39.4% | $222.5M +0.9% | $220.6M +62.7% | $135.6M +64.7% | $82.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $59.4M -11.6% | $67.2M +8.7% | $61.8M +23.9% | $49.9M +7.7% | $46.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $190.5M -34.2% | $289.7M +2.6% | $282.4M +52.3% | $185.5M +44.2% | $128.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.7M +314.6% | $893.0K -3.8% | $928.0K +24.7% | $744.0K -33.3% | $1.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$197.1M -54.0% | -$128.0M +19.8% | -$159.6M -27.8% | -$124.9M -271.0% | $73.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -2035.6% -1940.9pp | -94.7% +79.9pp | -174.6% +57.0pp | -231.6% -268.0pp | 36.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$184.6M -19.4% | -$154.6M +19.1% | -$191.0M -45.2% | -$131.6M -282.8% | $72.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1905.8% -1791.5pp | -114.4% +94.7pp | -209.1% +35.0pp | -244.1% -279.9pp | 35.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $14.1M -45.2% | $25.8M -16.8% | $31.0M +388.5% | $6.3M +15016.7% | $42.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$16.3M -163.5% | $25.6M -16.1% | $30.6M +413.4% | $6.0M +11122.2% | -$54.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$200.8M -55.8% | -$128.9M +19.7% | -$160.5M -27.8% | -$125.6M -274.6% | $71.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -2073.8% -1978.4pp | -95.4% +80.2pp | -175.6% +57.4pp | -233.0% -268.9pp | 35.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $43.3M +753.5% | -$6.6M +50.8% | -$13.5M -55.4% | -$8.7M -275.0% | $4.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$244.1M -99.6% | -$122.3M +16.8% | -$147.0M -25.7% | -$116.9M -274.6% | $67.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -2520.6% -2430.1pp | -90.5% +70.4pp | -160.9% +56.0pp | -217.0% -250.3pp | 33.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$5 -99.6% | -$2 +17.8% | -$3 -11.7% | -$2 -263.6% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$5 -99.6% | -$2 +17.8% | -$3 -11.7% | -$2 -279.0% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $53.8M +0.1% | $53.8M +1.0% | $53.2M +12.3% | $47.4M +7.1% | $44.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $53.8M +0.1% | $53.8M +1.0% | $53.2M +12.3% | $47.4M -2.3% | $48.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$991.01M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$806.22M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.15M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$501.06M
Verastem, Inc.
NASDAQ:VSTM
$286.27M
Bicycle Therapeutics plc
NASDAQ:BCYC
$276.89M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$271.44M
Gossamer Bio, Inc.
GOSS
$39.26M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PRTA generate?
Prothena Corporation plc (PRTA) reported $9.68M of revenue in fiscal 2025.
Is PRTA profitable?
Prothena Corporation plc (PRTA) reported -$244,092,000.00 of net income, with a net margin of -2520.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.